Faculty

Back to Index
William Stohl, MD, PhD
Professor of Medicine
Chief, Division of Rheumatology
Medicine
HMR 711 Health Sciences Campus Los Angeles
+1 323 442 1959

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren's syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

American College of Physicians: Fellow (FACP), 2012

Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

University of Pennsylvania School of Medicine: Upjohn Award, 1979

University of Pennsylvania School of Medicine: award conferred by, 1979

Arthritis Foundation Southern California Chapter: award conferred by, 2003

Arthritis Foundation Southern California Chapter: ORNG Application Instance for Person, 2003

University of Pennsylvania School of Medicine: ORNG Application Instance for Person, 1979

Arthritis Foundation Southern California Chapter: start date, 2003

University of Pennsylvania School of Medicine: start date, 1979

Arthritis Foundation Southern California Chapter: full name, 2003

University of Pennsylvania School of Medicine: full name, 1979

University of Pennsylvania School of Medicine: ORNG Application Instance Data value, 1979

Arthritis Foundation Southern California Chapter: ORNG Application Instance Data value, 2003

University of Pennsylvania School of Medicine: person in primary position, 1979

Arthritis Foundation Southern California Chapter: person in primary position, 2003

Arthritis Foundation Southern California Chapter: is primary position, 2003

University of Pennsylvania School of Medicine: is primary position, 1979

University of Pennsylvania School of Medicine: links, 1979

Arthritis Foundation Southern California Chapter: links, 2003

University of Pennsylvania School of Medicine: ORNG Application URL, 1979

Arthritis Foundation Southern California Chapter: ORNG Application URL, 2003

Arthritis Foundation Southern California Chapter: In The News, 2003

University of Pennsylvania School of Medicine: In The News, 1979

Arthritis Foundation Southern California Chapter: Department, 2003

University of Pennsylvania School of Medicine: Department, 1979

University of Pennsylvania School of Medicine: last name, 1979

Arthritis Foundation Southern California Chapter: last name, 2003

University of Pennsylvania School of Medicine: sort order, 1979

Arthritis Foundation Southern California Chapter: sort order, 2003

Arthritis Foundation Southern California Chapter: Person, 2003

University of Pennsylvania School of Medicine: Person, 1979

Arthritis Foundation Southern California Chapter: Organization, 2003

University of Pennsylvania School of Medicine: Organization, 1979

Arthritis Foundation Southern California Chapter: email address, 2003

University of Pennsylvania School of Medicine: email address, 1979

Arthritis Foundation Southern California Chapter: Required Scholarly Project Mentor, 2003

University of Pennsylvania School of Medicine: Required Scholarly Project Mentor, 1979

Arthritis Foundation Southern California Chapter: Person ID, 2003

University of Pennsylvania School of Medicine: Person ID, 1979

University of Pennsylvania School of Medicine: MediaLinks, 1979

Arthritis Foundation Southern California Chapter: MediaLinks, 2003

University of Pennsylvania School of Medicine: Keck School of Medicine of USC, 1979

Arthritis Foundation Southern California Chapter: Keck School of Medicine of USC, 2003

University of Pennsylvania School of Medicine: Stohl, William, 1979

Arthritis Foundation Southern California Chapter: Stohl, William, 2003

Arthritis Foundation Southern California Chapter: Professor, 2003

University of Pennsylvania School of Medicine: Professor, 1979

Arthritis Foundation Southern California Chapter: position in organization, 2003

University of Pennsylvania School of Medicine: position in organization, 1979

University of Pennsylvania School of Medicine: Faculty Rank, 1979

Arthritis Foundation Southern California Chapter: Faculty Rank, 2003

Arthritis Foundation Southern California Chapter: award or honor for, 2003

University of Pennsylvania School of Medicine: award or honor for, 1979

Arthritis Foundation Southern California Chapter: ct_data, 2003

University of Pennsylvania School of Medicine: ct_data, 1979

Arthritis Foundation Southern California Chapter: preferred title, 2003

University of Pennsylvania School of Medicine: preferred title, 1979

Arthritis Foundation Southern California Chapter: first name, 2003

University of Pennsylvania School of Medicine: first name, 1979

Arthritis Foundation Southern California Chapter: Agent, 2003

University of Pennsylvania School of Medicine: Agent, 1979

University of Pennsylvania School of Medicine: Medicine, 1979

Arthritis Foundation Southern California Chapter: Medicine, 2003

Arthritis Foundation Southern California Chapter: has ORNG Application Instance Data, 2003

University of Pennsylvania School of Medicine: has ORNG Application Instance Data, 1979

University of Pennsylvania School of Medicine: Award or Honor Receipt, 1979

Arthritis Foundation Southern California Chapter: Award or Honor Receipt, 2003

University of Pennsylvania School of Medicine: photo, 1979

Arthritis Foundation Southern California Chapter: photo, 2003

Arthritis Foundation Southern California Chapter: RequiredScholarlyProjectMentor, 2003

University of Pennsylvania School of Medicine: RequiredScholarlyProjectMentor, 1979

Arthritis Foundation Southern California Chapter: HR job title, 2003

University of Pennsylvania School of Medicine: HR job title, 1979

Arthritis Foundation Southern California Chapter: has faculty rank, 2003

University of Pennsylvania School of Medicine: has faculty rank, 1979

Publications

Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study. Clin Rheumatol. 2016 Nov 9. View in: PubMed

B cell-independent contribution of BAFF to murine autoimmune disease. Clin Immunol. 2016 Nov; 172:111-116. View in: PubMed

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. Arthritis Rheumatol. 2015 Sep; 67(9):2523-35. View in: PubMed

A dendritic-cell-stromal axis maintains immune responses in lymph nodes. Immunity. 2015 Apr 21; 42(4):719-30. View in: PubMed

Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells. Arthritis Rheumatol. 2015 Mar; 67(3):612-5. View in: PubMed

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015; 17(1):215. View in: PubMed

APRIL mediates peritoneal B-1 cell homeostasis. Immunol Lett. 2014 Aug; 160(2):120-7. View in: PubMed

Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fc? Receptor IIb Inhibitory Receptor. Arthritis Rheumatol. 2014 May; 66(5):1153-64. View in: PubMed

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014 Apr; 18(4):473-89. View in: PubMed

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9. View in: PubMed

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014 Jan 13; 211(1):45-56. View in: PubMed

Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013 Dec; 9(12):705-20. View in: PubMed

BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand. J Immunol. 2013 Aug 1; 191(3):1154-63. View in: PubMed

Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23. View in: PubMed

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89. View in: PubMed

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013 Apr; 65(4):1043-54. View in: PubMed

Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303. View in: PubMed

Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann Rheum Dis. 2012 Sep; 71(9):1567-72. View in: PubMed

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development? Curr Rheumatol Rep. Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development? Curr Rheumatol Rep. 2012 Aug; 14(4):303-9. View in: PubMed

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012 Aug; 39(8):1632-40. View in: PubMed

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis. 2012 Aug; 71(8):1289-96. View in: PubMed

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul; 64(7):2328-37. View in: PubMed

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012 May; 64(5):1610-9. View in: PubMed

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar; 71(3):351-7. View in: PubMed

The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012; 30(1):69-77. View in: PubMed

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30. View in: PubMed

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol. 2011 May; 23(3):305-10. View in: PubMed

B Cell and BAFF dependence of IFN-a-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011 Apr 15; 186(8):4984-93. View in: PubMed

Antibody-mediated coengagement of Fc?RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1; 186(7):4223-33. View in: PubMed

Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(4):228. View in: PubMed

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One. 2011; 6(8):e23629. View in: PubMed

Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010 Aug; 62(8):2432-42. View in: PubMed

Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010 Feb; 43(1):84-97. View in: PubMed

Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb; 62(2):392-401. View in: PubMed

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010; 12(2):111. View in: PubMed

Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol. 2009 Nov 1; 183(9):6021-9. View in: PubMed

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009 Nov; 60(11):3400-9. View in: PubMed

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78. View in: PubMed

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51. View in: PubMed

Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol. 2009 Feb 15; 182(4):2532-41. View in: PubMed

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009; 11(5):R143. View in: PubMed

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008 Aug; 58(8):2453-9. View in: PubMed

Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol. 2008 Jul 1; 181(1):833-41. View in: PubMed

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109. View in: PubMed

New and promising treatments for rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007 Jul; 36(7 Suppl):18-23. View in: PubMed

Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):351-8. View in: PubMed

Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochem Biophys Res Commun. 2006 Oct 20; 349(2):838-45. View in: PubMed

B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. 2006 Oct; 121(1):1-12. View in: PubMed

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006 Aug 15; 177(4):2671-80. View in: PubMed

TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol. 2006 Mar 15; 176(6):3321-9. View in: PubMed

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006 Mar; 54(3):723-32. View in: PubMed

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006; 8(1):R6. View in: PubMed

Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. Clin Immunol. 2005 Sep; 116(3):257-64. View in: PubMed

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005 Jul; 52(7):2080-91. View in: PubMed

BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun. 2005; 8:289-304. View in: PubMed

Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71. View in: PubMed

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004 Sep; 63(9):1096-103. View in: PubMed

Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis Rheum. 2004 Jul; 50(7):2227-39. View in: PubMed

MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904. View in: PubMed

Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets. 2004 Jun; 8(3):177-89. View in: PubMed

A therapeutic role for BLyS antagonists. Lupus. 2004; 13(5):317-22. View in: PubMed

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003 Dec; 48(12):3475-86. View in: PubMed

In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin Immunol. 2003 Sep; 108(3):182-9. View in: PubMed

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003 Apr; 48(4):982-92. View in: PubMed

SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther. 2003; 5(3):136-8. View in: PubMed

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002 Oct 15; 169(8):4314-21. View in: PubMed

Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol. 2002 Sep; 14(5):522-8. View in: PubMed

B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep. 2002 Aug; 4(4):345-50. View in: PubMed

B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol. 2002 Aug; 104(2):115-22. View in: PubMed

Powered bySC CTSI